AUROBINDO PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,186 INR | -1.23% |
|
-4.00% | +9.38% |
| 27/05 | Aurobindo Pharma Clocks Gains in Fiscal Q4 Consolidated Net Profit | MT |
| 27/05 | Transcript : Aurobindo Pharma Limited, Q4 2024 Earnings Call, May 27, 2024 |
| Sales 2024 | 290B 3.48B | Sales 2025 * | 316B 3.79B | Capitalization | 695B 8.33B |
|---|---|---|---|---|---|
| Net income 2024 | 31.73B 380M | Net income 2025 * | 39.08B 469M | EV / Sales 2024 | 2.2 x |
| Net cash position 2024 * | 18.34B 220M | Net cash position 2025 * | 24.71B 296M | EV / Sales 2025 * | 2.12 x |
| P/E ratio 2024 |
20.1
x | P/E ratio 2025 * |
17.8
x | Employees | 23,451 |
| Yield 2024 * |
0.36% | Yield 2025 * |
0.42% | Free-Float | 47.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aurobindo Pharma
More recommendations
More press releases
More news
| 1 day | -1.23% | ||
| 1 week | -4.00% | ||
| 1 month | +2.79% | ||
| 3 months | +15.33% | ||
| 6 months | +13.84% | ||
| Current year | +9.38% |
1 week
1 162.65
1 238.70
1 month
1 097.101 245.70
Current year
958.501 245.70
1 year
652.351 245.70
3 years
397.201 245.70
5 years
288.851 245.70
10 years
288.851 245.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 26/86/26 | |
| Director of Finance/CFO | - | 01/13/01 | |
B. Adi Reddy
CMP | Compliance Officer | - | 01/16/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 26/86/26 | |
| Founder | 66 | 26/86/26 | |
| Director/Board Member | 64 | 27/03/27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.32% | 6 M€ | +6.07% | - | |
| 0.22% | 19 M€ | +6.80% | ||
| 0.12% | 11 M€ | +2.67% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 1,186 | -1.23% | 2,973,908 |
| 30/24/30 | 1,200 | -1.51% | 913,732 |
| 29/24/29 | 1,219 | -0.17% | 1,130,292 |
| 28/24/28 | 1,221 | +2.06% | 2,079,792 |
| 27/24/27 | 1,196 | -3.13% | 4,238,829 |
Delayed Quote NSE India S.E., May 31, 2024 at 05:13 pm IST
More quotes
Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families :
- generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases;
- active pharmaceutical ingredients.
At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil.
Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,186
INR
Average target price
1,292
INR
Spread / Average Target
+8.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.38% | 8.32B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- AUROPHARMA Stock
